La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Amoy Diagnostics Résultats passés
Passé contrôle des critères 2/6
Amoy Diagnostics has been growing earnings at an average annual rate of 15.5%, while the Biotechs industry saw earnings growing at 9.9% annually. Revenues have been growing at an average rate of 13.5% per year. Amoy Diagnostics's return on equity is 15.8%, and it has net margins of 24.7%.
Informations clés
15.5%
Taux de croissance des bénéfices
15.4%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 11.3% |
| Taux de croissance des recettes | 13.5% |
| Rendement des fonds propres | 15.8% |
| Marge nette | 24.7% |
| Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Amoy Diagnostics' (SZSE:300685) Upcoming Dividend Will Be Larger Than Last Year's
May 27
Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%
Apr 24Amoy Diagnostics (SZSE:300685) Could Easily Take On More Debt
Apr 18What Amoy Diagnostics Co., Ltd.'s (SZSE:300685) 33% Share Price Gain Is Not Telling You
Mar 02Is Amoy Diagnostics Co., Ltd. (SZSE:300685) Worth CN¥22.0 Based On Its Intrinsic Value?
Mar 01Ventilation des recettes et des dépenses
Comment Amoy Diagnostics gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 1,128 | 279 | 424 | 218 |
| 31 Mar 24 | 1,082 | 268 | 402 | 215 |
| 31 Dec 23 | 1,044 | 261 | 390 | 203 |
| 30 Sep 23 | 951 | 213 | 383 | 204 |
| 30 Jun 23 | 908 | 301 | 378 | 189 |
| 31 Mar 23 | 831 | 267 | 364 | 173 |
| 01 Jan 23 | 842 | 264 | 367 | 175 |
| 30 Sep 22 | 871 | 287 | 395 | 168 |
| 30 Jun 22 | 911 | 218 | 390 | 166 |
| 31 Mar 22 | 949 | 250 | 388 | 162 |
| 01 Jan 22 | 917 | 240 | 374 | 156 |
| 30 Sep 21 | 890 | 231 | 373 | 138 |
| 30 Jun 21 | 844 | 211 | 364 | 130 |
| 31 Mar 21 | 811 | 198 | 356 | 127 |
| 31 Dec 20 | 728 | 180 | 339 | 115 |
| 30 Sep 20 | 650 | 153 | 308 | 115 |
| 30 Jun 20 | 595 | 138 | 292 | 106 |
| 31 Mar 20 | 550 | 129 | 284 | 96 |
| 31 Dec 19 | 578 | 135 | 294 | 94 |
| 30 Sep 19 | 541 | 140 | 265 | 87 |
| 30 Jun 19 | 502 | 135 | 241 | 86 |
| 31 Mar 19 | 469 | 134 | 215 | 85 |
| 31 Dec 18 | 439 | 127 | 201 | 78 |
| 30 Sep 18 | 398 | 122 | 186 | 69 |
| 30 Jun 18 | 384 | 120 | 156 | 84 |
| 31 Mar 18 | 357 | 103 | 161 | 64 |
| 31 Dec 17 | 330 | 94 | 157 | 51 |
| 30 Sep 17 | 315 | 82 | 163 | 39 |
| 30 Jun 17 | 288 | 78 | 193 | 0 |
| 31 Mar 17 | 258 | 67 | 180 | 0 |
| 31 Dec 16 | 253 | 67 | 181 | 0 |
| 30 Jun 16 | 220 | 42 | 168 | 0 |
| 31 Mar 16 | 198 | 32 | 157 | 0 |
| 31 Dec 15 | 177 | 21 | 147 | 0 |
| 31 Dec 14 | 107 | 19 | 82 | 0 |
| 31 Dec 13 | 74 | 22 | 52 | 0 |
Des revenus de qualité: 300685 has high quality earnings.
Augmentation de la marge bénéficiaire: 300685's current net profit margins (24.7%) are lower than last year (33.2%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 300685's earnings have grown by 15.5% per year over the past 5 years.
Accélération de la croissance: 300685's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Bénéfices par rapport au secteur d'activité: 300685 had negative earnings growth (-7.5%) over the past year, making it difficult to compare to the Biotechs industry average (-7.5%).
Rendement des fonds propres
ROE élevé: 300685's Return on Equity (15.8%) is considered low.